Amgen Pulled Up Over Anti-Biosimilar Pegfilgrastim Promotion

FDA Cautions Originator Over ‘Misleading’ Claims On Neulasta Onpro

 
• By David Wallace
  
Amgen was rebuked by the FDA over promotion for its Neulasta Onpro • Source: illustration/FDA

More from Biosimilars

More from Products